LQDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Liquidia Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$34.13−0.22 (-0.64%)
Close on Oct 19, 2026
- Market cap
- $3.46B
- P/E (TTM)
- 24.6
- Dividend yield
- –
Liquidia Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Product sales, net | $148.29M | – | – | – | – | 93.7% | – |
| Service revenue, net | $10.03M | $14.00M | $17.49M | $739.63K | $0 | 6.3% | -28.3% |
| Collaboration [Member] | – | – | – | $0 | $8.07M | – | – |
| Research and Development Services [Member] | – | – | – | $0 | $200 | – | – |
| Royalty [Member] | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Liquidia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.